This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS)

  • End date
    Jun 30, 2024
  • participants needed
  • sponsor
Updated on 19 January 2022
ct scan
heart failure
fluid overload
acute respiratory distress
positive end expiratory pressure
assisted breathing
assisted ventilation


The study is composed of two parts. In part A of the study two active doses of inhaled pegylated adrenomedullin (PEG-ADM) will be compared regarding safety and efficacy to a substance that has no therapeutic effect (placebo) in order to find an optimal and safe of the study drug. In part B of the study the highest dose that is considered safe and has demonstrated efficacy will be taken forward to collect information how well patients suffering from Acute Respiratory Distress Syndrome (ARDS) respond to treatment with inhaled pegylated adrenomedullin (PEG-ADM) compared to treatment with placebo. ARDS is a type of lung failure that cause fluid to build up in the lungs making breathing difficult or impossible.

Condition Acute Respiratory Distress Syndrome
Treatment BAY1097761 Active Dose 1, Placebo to BAY1097761, BAY1097761 Active Dose 2
Clinical Study IdentifierNCT04417036
Last Modified on19 January 2022


Yes No Not Sure

Inclusion Criteria

≥18 years of age at the time of inclusion into study
Invasively mechanically ventilated acute respiratory distress syndrome [ARDS] patients (diagnosed according to Berlin definition of ARDS, including positive end-expiratory pressure [PEEP] of ≥5 cm H2O, X-ray (or CT scan) indicative of ARDS: bilateral opacities not fully explained by cardiac failure, fluid overload, lobar/lung collapse, effusions or nodules)
Initial diagnosis of mild, moderate or severe ARDS prior to study inclusion, with acute onset of ARDS within 1 week after suspected trigger factor of
Prior to randomization, hypoxemia with PaO2:FiO2 ≤300 mmHg continuously observed for a
period of ≥4 hours (with values of ≥2 arterial blood gas [ABG] analyses during
For Study Part A: ARDS patients for whom measurements of extra-vascular lung water are regarded as medically indicated by the treating physician, and these measurements are planned as part of their clinical care, from Study Day 1 up to Study Day 7 (if then still intubated)
that time, with the last value obtained timely (generally ≤3 hours) prior to
randomization), under ventilation with minimum PEEP ≥8 cm H2O
Time from first meeting the last diagnostic ARDS criterion (Berlin criteria) to randomization must be ≤48 hours

Exclusion Criteria

Any value of a PaO2:FiO2 ratio >300 mmHg within a time interval of 4 hours before randomization
Rescue therapy (e.g. inhalation of nitric oxide gas and/or inhalation of prostacyclin analogues, or extra corporeal membrane oxygenation [ECMO] / extra corporeal CO2 removal [ECCO2R]) already initiated at screening and/or Study Day 1 (prior to first dose of the study intervention)
Moribund participants not expected to survive 24 hours (clinical decision)
Expected duration of invasive mechanical ventilation less than 48 hours (clinical decision)
History of co-morbidities requiring long-term/home oxygen use (e.g. severe chronic obstructive pulmonary disease [COPD], pulmonary fibrosis) or non-invasive ventilation (except for sleep apnea management), or making weaning per se improbable (e.g. ALS, muscular dystrophy)
Smoke inhalation injury, extensive burns or trauma/head injury as concomitant condition
History of pneumectomy, lung lobectomy or lung transplant
Diffuse alveolar hemorrhage from vasculitis
Current lung malignancy (incl. lung metastasis), or other malignancy requiring chemotherapy or radiation within the last month
Chronic kidney disease with a history of renal replacement therapy (e.g. dialysis)
Chronic liver disease Child-Pugh Class C
Chronic heart failure NYHA IV
Known hypersensitivity to polyethyleneglycol (PEG, Macrogol)
Participation in other interventional studies involving pharmacological interventions, or biological or cell therapy interventions
History of SARS-CoV-2 infection within 6 weeks prior to study inclusion, or current diagnosis of COVID-19 at screening and/or randomization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note